Shots: Celenex (a Nationwide Children Hospital spin out) to receive an upfront of $100M cash, development milestones up to $15M, and may be eligible for up to $75M tiered sales ($500M /$750M) milestone payments with no royalties, $262M for BLA/MAA submission and approval milestones across multiple programs Amicus will not pay >$75M over the next […]Read More
Shots: The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease, evaluating its safety and efficacy The FACET or Study 011 resulted in reduction of substrate (KIC GL-3) accumulation in the kidney capillaries Galafold (migalastat) 123mg is a novel PO dosage form of alpha Galactosidase A used for […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
